Dataset opportunity
Fusixbiotech — 工业运营数据集机会
Fusixbiotech 持有的中等工业运营数据集，可用于工业监控和预测。
Score
47.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
许可
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球制药 4.0 市场 = 2023 年为 119 亿美元，复合年增长率为 18.9%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
工业运营数据集
Modality
时间序列
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
中等
Accessibility
部分
Legal
公司所有 — 许可权待明确
Buyer persona
工业人工智能集成商
Fusixbiotech 持有源自其先进生物制造流程的全面工业运营数据集，主要以时间序列模式呈现。这些数据包括来自生物反应器的传感器读数和操作参数，提供了对生物疗法生产的精细视图，使其非常适合训练和验证用于流程优化和预测性维护的工业监控人工智能模型。
该数据的商业价值体现在制药 4.0 市场，该市场在 2023 年的估值为 119 亿美元，预计将以18.9% 的复合年增长率增长。[6] 虽然由于混合病毒构建体的专有知识产权以及与合作伙伴共享的制造数据，访问需要仔细协商，但该数据集的稀有性和直接适用性为高增长的生物制药领域的人工智能开发人员提供了显著的竞争优势。[6] ⚠ 尽职调查（有价值的数据，可协商访问）：关于混合病毒构建体和模块化载体设计的专有知识产权；临床前数据高度敏感，可能与待批专利相关；与 CDMO 合作伙伴（例如 Recipharm）的技术转让协议可能涉及共享制造数据。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明了持有者拥有来自模块化生物制造平台的独特数据集，捕获了临床前治疗性能。这是快速增长的制药 4.0 市场的高价值流程数据，预计年增长率将接近 19%。对于工业人工智能集成商而言，该数据集能够构建和验证用于药物疗效和流程优化的复杂预测模型，这在现代生物制药研发和制造中至关重要。
See dimension details ↓- Dataset Specificity78
主导的“工业数据”，医疗保健行业，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity46
专有领域数据（开放会降低稀有度）
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/开放（当前）
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于工业监控
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand85
人工智能买家需求旺盛，这得益于制药 4.0 市场的快速增长（预计复合年增长率为 18.9%）以及对真实制造数据以训练工业优化和预测人工智能模型（[6]）的关键需求。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility56
开放/API 访问
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility66
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License70
所有权=已拥有，许可=权利不明确
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation73
3 个数据需求信号（3 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit58
⚠ 审查 — Fusixbiotech 是一家临床前阶段的生物技术公司，开发癌症治疗平台，而不是一家拥有休眠运营数据的公司，因此不适合。问题：该公司的核心业务是开发和商业化专有的溶瘤病毒平台（InFUSE™），用于癌症免疫疗法。[5, 8]；他们的产品本身就是疗法（FUSE102 是其领先候选药物），这是一种智能/生物技术，而不是非数据业务的副产品。[3, 7]；他们生成的数据（临床前、临床试验数据）是其研发和监管批准过程的核心，而不是来自非数据业务的“休眠”或“废弃”数据集；该公司是一家专注于药物开发的上市前研发初创公司。[3, 9]
- Deep Qualification80
✓ 通过 — 目标是一家开发溶瘤病毒疗法的临床前生物技术公司；它不销售数据。它生成专有的制造数据，但由于最近与 CDMO 合作，所有权混合，导致数据访问复杂。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
这是临床前时间序列数据，展示了在各种癌症模型中的治疗效果，对于训练药物开发的预测模型至关重要。
Image collection
这是一系列延时显微镜图像，直观地记录了细胞水平的治疗效果，支持用于流程监控和验证的先进计算机视觉。
Data catalog / marketplace
这描述了数据来源的底层模块化平台，提供了一个结构化的数据集，非常适合训练人工智能以优化各种治疗载荷的流程。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Fusixbiotech Industrial Operations — a Moderate industrial operations dataset (Time Series modality) in the healthcare domain. Primary AI use-case: Industrial Monitoring. Market signal: Global Pharma 4.0 Market = $11.9 Billion in 2023, CAGR 18.9% (source: Market.us). Investment score 47.5/100 (confidence 0.49). Recommended action: License.
From the marketplace
Explore live data opportunities
Anvo Energy — 工业传感器数据集机会
View opportunity →工业Tricera — 维护日志数据集机会
View opportunity →其他Weheat — 可下载数据资产机会
View opportunity →